Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Elizabeth Lejeune

Medical Oncology Lafayette, LA Medical Doctor

NPI 1912351370 CMS profile 7216438

1211 Coolidge Blvd Ste 100, Lafayette, LA 70503

Open in the dashboard

General payments

$5,619

292 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Elizabeth Lejeune of Lafayette, LA is reported in the CMS Open Payments database as having received $5,619 across 292 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 53rd percentile of Medical Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,230 59
2024 General $1,077 52
2023 General $1,399 72
2022 General $679 40
2021 General $886 43
2020 General $84 6
2019 General $265 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Elizabeth Lejeune
  • Medical Oncology median
  • Middle half of Medical Oncology
  • National median

In program year 2025, general payments to Elizabeth Lejeune were reported at $1,230. Among 3,316 Medical Oncology profiles paid that year, the median was $1,128 and the middle half received between $147 and $5,675.

Show as a table
Year Elizabeth Lejeune Medical Oncology median Middle half National median
2019 $265 $968 $140–$6,658 $163
2020 $84 $747 $102–$5,891 $114
2021 $886 $430 $50–$4,098 $132
2022 $679 $812 $127–$4,907 $149
2023 $1,399 $957 $144–$5,248 $160
2024 $1,077 $1,042 $149–$5,650 $164
2025 $1,230 $1,128 $147–$5,675 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $515 19 payments
  2. Novartis Pharmaceuticals Corporation $474 27 payments
  3. Pfizer Inc. $452 26 payments
  4. E.R. Squibb & Sons, L.L.C. $354 20 payments
  5. Merck Sharp & Dohme Corporation $327 17 payments
  6. Daiichi Sankyo Inc. $291 13 payments
  7. Celgene Corporation $265 15 payments
  8. Incyte Corporation $257 16 payments
  9. Genentech USA, Inc. $239 7 payments
  10. GlaxoSmithKline, LLC. $178 6 payments
  11. Other $2,268 126 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,550 291 payments
  2. Education $68 1 payment
Products named General payments · program years 2019–2025
  1. KEYTRUDA $292 15 payments
  2. ENHERTU $276 12 payments
  3. REBLOZYL $215 12 payments
  4. IBRANCE $205 11 payments
  5. LYNPARZA $201 10 payments
  6. KISQALI $194 10 payments
  7. CALQUENCE $186 4 payments
  8. JAKAFI $164 11 payments
  9. VENCLEXTA $141 2 payments
  10. OPDIVO $138 7 payments
  11. Other $4,499 253 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

823

Median for Internal Medicine: 777

Drug cost

$115,914

Median for Internal Medicine: $73,373

Branded share of claims

19.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Venclexta Venetoclax Brand 16 $70,843
Eliquis Apixaban Brand 47 $28,299
Xarelto Rivaroxaban Brand 12 $7,685
Letrozole Generic 126 $1,946
Ondansetron Odt Ondansetron Brand 37 $910
Prochlorperazine Maleate Generic 86 $778
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 38 $712
Dexamethasone Generic 45 $584
Ondansetron Hcl Generic 70 $535
Levofloxacin Generic 16 $513

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$76,151

Medicare's payments for the services billed

Medicare patients

280

Average age 74

Services billed

852

164 women, 116 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 51%
Arthritis 50%
Diabetes 40%
Ischemic heart disease 36%
Chronic kidney disease 31%
Depression 28%
Atrial fibrillation 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 37 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENHERTU
  • Daiichi Sankyo Inc. $99
  • AstraZeneca Pharmaceuticals LP $18
$117 — —
REBLOZYL
  • Celgene Corporation $82
$82 — —
OPDUALAG
  • E.R. Squibb & Sons, L.L.C. $55
  • Celgene Corporation $19
$74 — —
KEYTRUDA
  • Merck Sharp & Dohme Corporation $58
$58 — —
Doptelet
  • Sobi, Inc $51
$51 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 37 with Patron

Records

292 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record